Home > Browse Research > Life Sciences > Pharmaceuticals > Diseases & Conditions > Asthma

Asthma: market research reports

Asthma is a disease characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person. This condition is caused by the inflammation of the air passages in the lungs. It affects the sensitivity of the nerve endings in the airways so that they become easily irritated. In an attack, the lining of the passages swells, causing the airways to narrow and reducing the flow of air in and out of the lungs.

Although asthma is a chronic obstructive condition, it is not considered a part of COPD as this refers specifically to combinations of bronchiectasis, chronic bronchitis, and emphysema. Unlike these diseases, the airway obstruction in asthma is usually reversible. However, if left untreated, asthma can result in chronic inflammation of the lungs and irreversible obstruction. In contrast to emphysema, asthma affects the bronchi, not the alveoli. Public attention in the developed world has increased recently because of its rapidly increasing prevalence, affecting up to a quarter of urban children.

The strongest risk factors for developing asthma are a person’s exposure to allergens and a family history of asthma or allergy. Exposure to tobacco smoke and exposure to chemical irritants in the workplace are additional risk factors. Workplace conditions, such as exposure to fumes, gases or dust, are responsible for 11% of asthma cases worldwide.

Asthma market research reports and industry analysis

Allergic Asthma – Pipeline Review, H1 2013 5/27/2013 \| published by: Global Markets Direct ... for Allergic Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Asthma. Allergic Asthma - Pipeline Review, Half Year ... \| read more...	$2,000.00
EpiCast Report: Asthma - Epidemiology Forecast to 2022 5/27/2013 \| published by: GlobalData ... et al., 2004). The 2004 Global Initiative for Asthma (GINA) report estimated that prevalence of asthma in the general population varied widely in different countries around the world, with proportions ranging between 1% in Albania ... \| read more...	$3,995.00
Asthma – Executive Market Summary 2013 5/20/2013 \| published by: Timely Data Resources, Inc. ... on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the asthma market, as well as sales of leading drugs and therapies are provided. \| read more...	$950.00
Chronic Obstructive Pulmonary Disease (COPD) – Executive Market Summary 2013 5/20/2013 \| published by: Timely Data Resources, Inc. ... information on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the COPD market, as well as sales of leading drugs and therapies are ... \| read more...	$950.00
Conference Documentation: Asthma & COPD 4/15/2013 \| published by: SMI Publishing, Ltd ... previous Asthma & COPD, and COPD: Novel Therapeutics and Management Strategies events, Asthma & COPD 2013 will continue to bring forward leading industry experts and esteemed academic KOLs in the field to discuss the latest ... \| read more...	$788.78
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2013 3/18/2013 \| published by: Global Markets Direct ... information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic ... \| read more...	$2,000.00
Asthma – Pipeline Review, H1 2013 3/18/2013 \| published by: Global Markets Direct ... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. Asthma - Pipeline Review, Half Year is built using data and information ... \| read more...	$2,000.00
Asthma Global Clinical Trials Review, H1, 2013 1/31/2013 \| published by: GlobalData ... to the clinical trials on Asthma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of ... \| read more...	$2,500.00
Asthma 1/1/2013 \| published by: Apollo Managed Care, Inc. Clinical evaluation and management guideline. Authoritative references. Resources include patient/parent instruction sheets and education aids, national guideline summaries and web links. Updated annually. \| read more...	$119.00
Chronic Obstructive Pulmonary Disease (COPD) 1/1/2013 \| published by: Apollo Managed Care, Inc. ... and management of COPD and obstructive sleep apnea. Evidence-based criteria for screening, tests, and treatments including lung transplantation, smoking cessation programs, durable medical equipment and oxygen are described. Authoritative references and resources with web links. \| read more...	$119.00
2012 Pharmaceuticals Research Review 12/1/2012 \| published by: BCC Research ... human antifungal therapeutics with a heavy focus on therapeutics in early development. Profiles of manufacturers of leading asthma and chronic obstructive pulmonary disease (COPD) prescription drugs. Comprehensive analysis of the market for genitourinary drugs on ... \| read more...	$950.00
Chronic Obstructive Pulmonary Disease (COPD) Global Clinical Trials Review, H2, 2012 11/20/2012 \| published by: GlobalData ... (COPD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Obstructive Pulmonary Disease (COPD). It includes an overview of the trial numbers and their recruitment status as ... \| read more...	$2,500.00
Global Preventive Asthma Drugs Market 2011-2015 11/16/2012 \| published by: Infiniti Research Limited ... of asthma. The Global Preventive Asthma Drugs market has also been witnessing the trend of an increased focus on contract manufacturing outsourcing. However, the increasing generic competition could pose a challenge to the growth of ... \| read more...	$1,500.00
How Will Payer and Prescriber Attitudes Toward Emerging LABA/LAMA and LABA/ICS Fixed-Dose Combinations Shape the COPD Markets in the EU5? 11/6/2012 \| published by: Decision Resources ... of delivering two drugs in one inhaler, these FDCs are among the most prescribed drugs for COPD. Physicians also favor Boehringer Ingelheim/Pfizer’s Spiriva (tiotropium), a long-acting muscarinic antagonist (LAMA). However, the European COPD therapy market ... \| read more...	$10,000.00
Conference Documentation: COPD: Novel Therapeutics and Management Strategies 10/22/2012 \| published by: SMI Publishing, Ltd ... presentations, this event will be the perfect opportunity to hear presentations on the latest hot topics surrounding COPD and to network with key industry professionals. This conference continues to promote increased awareness of COPD and ... \| read more...	$788.78
What are the Market Access Levers and Hurdles Facing Additional LABA/ICS Fixed-Dose Combinations for Asthma in the EU5? 10/12/2012 \| published by: Decision Resources ... SpA), and Flutiform (formoterol/fluticasone propionate; SkyePharma/Mundipharma). Offering efficacy and the convenience of delivering two drugs in one inhaler, these LABA/ICS FDCs are among the most prescribed drugs for the indication. The European LABA/ICS FDC asthma ... \| read more...	$10,000.00
Chronic Obstructive Pulmonary Disease 10/4/2012 \| published by: Decision Resources ... awareness of the disease continue, and the use of spirometry to diagnose COPD becomes more widespread. The expanding COPD patient population has great unmet need because truly disease-modifying pharmacotherapies are lacking; current treatments merely alleviate ... \| read more...	$10,000.00
Epidemiology: COPD in China – Aging, population growth, and increased survival will drive up prevalent cases over the next decade 10/2/2012 \| published by: Datamonitor ... from approximately 42 million to nearly 56 million. This increase will be driven by demographic changes over the forecast period, including increased survival and a larger aged population. Features and benefits Gain insight to market ... \| read more...	$3,800.00
Asthma Market Forecast 9/7/2012 \| published by: Datamonitor ... negative, as key products face generic entry. However, by 2021, Datamonitor forecasts a return to positive growth such that the market will maintain value, with a CAGR over 2012–21 of 0.1%. Introduction Access Datamonitor’s patient-based ... \| read more...	$11,400.00
Market and Product Forecasts: Asthma – Premium products to offset loss to generics 9/7/2012 \| published by: Datamonitor ... negative, as key products face generic entry. However, by 2021, Datamonitor forecasts a return to positive growth such that the market will maintain value, with a CAGR over 2012–21 of 0.1%. Scope Access Datamonitor’s patient-based ... \| read more...	$11,400.00
China Asthmatic Prescription Drugs Sales Data 2006-2011 9/1/2012 \| published by: Draco Healthcare Consulting LLC ... and drug purchasing data from extensive hospital coverage in 16 major cities and more than 300 hospitals. Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, ... \| read more...	$8,000.00
Chinese Markets for Asthma Treatment Drugs 9/1/2012 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021 are presented. Major producers ... \| read more...	$2,000.00
Global Markets for Asthma and COPD Drugs 8/1/2012 \| published by: BCC Research ... increasing at a five-year compound annual growth rate (CAGR) of 4.4%. Combination asthma/COPD drugs are expected to be worth $17.4 billion in 2012 and should reach $21.3 billion in 2017, a CAGR of 4.1%. The ... \| read more...	$5,450.00
Market and Product Forecasts: Asthma in China – Market set to fragment as novel therapies launch 7/31/2012 \| published by: Datamonitor ... novel products will increase the product offering on the market, however, with only a fraction of the patient pool market receiving asthma treatment, considerable untapped patient potential will remain. Scope Access Datamonitor’s patient-based asthma market ... \| read more...	$11,400.00
Epidemiology: Asthma – Stable prevalence rates in all age groups will lead to stable case numbers 7/18/2012 \| published by: Datamonitor ... rates and modest population increases are responsible for the small change in the number of cases during this period. Introduction Gain insight into market potential, including robust 10-year epidemiology forecasts of active diagnosed prevalent asthma ... \| read more...	$5,700.00

< prev 1 2 3 4 next >